Thought Leadership
FDA Emergency Use Authorizations
April 1, 2020
Chad Landmon
Lexis Practice Advisor Journal

In order to assist pharmaceutical, biologic, medical device, and diagnostic companies who are developing products to address the coronavirus crisis, Chad Landmon co-authored and published an article on FDA Emergency Use Authorizations (EUAs) at the request of the Lexis Practice Advisor Journal for a special coronavirus edition. The article offers an overview of the legal and regulatory framework for EUAs, provides practical tips for obtaining an EUA, and introduces considerations for importing and exporting under an EUA. Click here to access the article. The article will also be available on the Lexis Practice Advisor.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.